Abstract
Genine Winslow is the CEO and co-founder of Chameleon Biosciences, a biotechnology company she founded in 2017 focused on safer, more effective gene therapies. At Chameleon, Genine combines her backgrounds in both immunology and gene therapy to engineer a next generation AAV based vector for systemic repeat dosing for children and adults who today cannot be treated with conventional gene therapies. Prior to Chameleon, Winslow has led gene therapy scientific initiatives at multiple companies including Audentes Therapeutics, BioMarin, BlueBird Bio, and Cell Genesys. On March 30th 2022, David McCall, Editor, Cell and Gene Therapy Insights spoke to Genine Winslow about overcoming the immune-related shortfalls of AAV. This article has been written based on that interview.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
